Skip to content
RushPR News – Lifestyle
Author:
Asgard Therapeutics
Asgard Therapeutics awarded €2.5m EIC Accelerator grant to advance lead program AT-108 toward the clinic
November 19, 2026
Asgard Therapeutics announces publication in Immunity demonstrating induction of cancer-fighting tertiary lymphoid structures across seven tumor types – and will present new AT-108 biomarker data at SITC 2026
November 4, 2026